MeSH tree: C15.378.463
At the American Society of Hematology Conference in Orlando, new results from the MajesTEC-3 study show that combining teclistamab with daratumumab could help people with myeloma whose cancer has come back or hasn't responded ...
Dec 9, 2025
0
17
Patients who receive T-cell redirecting therapies are typically hospitalized for several days after treatment to watch for side effects. Now new research by Fox Chase Cancer Center physicians shows that these patients can ...
Dec 9, 2025
0
9
In a new study, researchers at Children's Hospital of Philadelphia (CHOP) have uncovered an alarming trend—the proportion of newborn infants not receiving preventative vitamin K shots has increased by 77% since 2017. The ...
Dec 8, 2025
0
19
Research presented December 8 at the American Society of Hematology Conference in Florida, has shown that a new kind of CAR T-cell therapy, which generates CAR T-cells inside the body, could offer a faster, easier and more ...
Dec 8, 2025
0
11
Sensitive tests designed to detect very small numbers of remaining leukemia cells after treatment, known as measurable residual disease (MRD), may provide an early and reliable indicator of long-term outcomes for patients ...
Dec 8, 2025
0
8
Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted by researchers at Sylvester ...
Dec 6, 2025
0
30
Biased or misleading medical advice shared by social media influencers can cause harm and requires coordinated action by governments and platforms to protect the public, argue experts in The BMJ.
Dec 3, 2025
0
22
Hereditary hemorrhagic telangiectasia (HHT) is the second most common inherited bleeding disorder worldwide, affecting one in 3,800 persons. HHT's hallmark symptom is chronic nosebleeds, which often occur alongside other ...
Nov 26, 2025
0
24
Patients with newly diagnosed multiple myeloma (NDMM) treated at a specialized clinic have improved outcomes, with median overall survival (OS) of 152 months, according to a research letter published in the November issue ...
Nov 24, 2025
0
9
The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a single-agent treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM).
Nov 13, 2025
0
23
